HTA56 The Post-Brexit UK Access Landscape: Does Project Orbis Significantly Accelerate Patient Access for Oncology Drugs in the UK Versus Europe?

Abstract

Following Brexit, the MHRA has become the standalone regulator for medicines in the UK (except Northern Ireland). To ensure timely access to innovative oncology products, the UK joined Project Orbis, an FDA-led review programme. This research compares UK reimbursement outcomes for medicines approved through Project Orbis with EU4.